OTS.at - aktuelle Inhalte in Text, Bild, Ton und Video

Grünenthal Group

Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia

Aachen, Germany (OTE) - Aachen, Germany (ots)

02.06.2025, 10:00:33
/
OTE0002

Grünenthal Group

Maren Thurow starts as new Head Global Communications at Grünenthal

Aachen (OTE) - Maren Thurow has today assumed the role of Vice President and Head Global Communications at Grünenthal. She succeeds Florian Dieckmann, who has played a key role in evolving the company’s Communications department...

20.05.2025, 10:36:02
/
OTE0001

Grünenthal Group

Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal

Aachen, Germany & Toronto, Canada, (OTE) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that...

24.02.2025, 15:44:17
/
OTE0001

Grünenthal Group

Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer

Aachen, Germany (OTE) - Grünenthal announced today that Prof. Dr. Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective 01 February 2025.

09.01.2025, 10:27:48
/
OTE0001

Grünenthal Group

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neur

Aachen, Germany/Morristown, N.J. (OTE) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post- surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10...

07.11.2024, 10:39:32
/
OTE0001

Grünenthal Group

First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist

Aachen, Germany (OTE) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy...

22.10.2024, 12:13:17
/
OTE0001

Grünenthal Group

Grünenthal appoints Dr. Jan Adams as Chief Commercial Officer

Aachen, Germany (OTE) - Grünenthal announced today that Jan Adams, M.D., currently Chief Scientific Officer (CSO) and member of the Corporate Executive Board, will assume the role of Chief Commercial Officer (CCO)...

30.09.2024, 11:39:47
/
OTE0002

Grünenthal Group

Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®

Aachen, Germany (ots) - Grünenthal today announced the acquisition of US-based Valinor Pharma, LLC (“Valinor”) and its product Movantik® (naloxegol), with a total deal value of approx. $250 million inclusive...

22.07.2024, 09:15:28
/
OTE0001

Grünenthal Group

Grünenthal Quito site celebrations/Grünenthal / More information
via ots and www.presseportal.de/en/nr/118252 / The use of this image
for editorial purposes is permitted and free of charge provided that
all conditions of use are complied with. Publication must include
image credits.

Grünenthal announces significant investments in its Latin America production sites,

further securing reliable medicine supply for patients

17.07.2024, 09:46:03
/
OTS0030

Grünenthal Group

BehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics

NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor...